fashion -WSS

fashion

author：hotspot 2025-09-06 01:57:36 - browse：12886

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Bird flu reported in person exposed to presumably infected cattle

WSS

With trial win, GSK could get blood cancer drug back on market

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

See how much Covid

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Innovation in antibiotics is ailing. 'Brain drain' may kill it

hotspot

fashion

explore

Peter Hotez and the public health issue of online harassment

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

BioMarin wins approval for gene therapy to treat hemophilia A

Scientists uncover potential path to treating deadly childhood tumor

Dobbs anniversary: the lost opportunity of abortion as health care

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Alkermes shareholders re

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

entertainment

Change Healthcare can notify patients about the breach, HHS says

Scientific mystery highlights the blind spots in genomics databases

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Republican states more likely to report Covid vaccine side effects

Harvard scientists, with Google, unveil the most detailed brain map ever

Scientific mystery highlights the blind spots in genomics databases

leisure time

focus

focus

hotspot